Publicaciones en las que colabora con Luis de la Cruz-Merino (9)

2022

  1. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2019

  1. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2016

  1. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1044-1050

  2. Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience

    Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1147-1157

  3. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study

    PLoS ONE, Vol. 10, Núm. 4

  2. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137